These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 11712793)

  • 21. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT.
    Tsai CS; Chang TC; Lai CH; Tsai CC; Ng KK; Hsueh S; Yen TC; Hong JH
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1506-12. PubMed ID: 15050330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
    Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
    Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer.
    Kitajima K; Murakami K; Yamasaki E; Hagiwara S; Fukasawa I; Inaba N; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Feb; 22(2):103-9. PubMed ID: 18311534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of 18F-FDG PET/CT in detecting pelvic lymph-node metastases in patients with early-stage uterine cervical cancer: comparison with MRI findings.
    Lv K; Guo HM; Lu YJ; Wu ZX; Zhang K; Han JK
    Nucl Med Commun; 2014 Dec; 35(12):1204-11. PubMed ID: 25222911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
    Yildirim Y; Sehirali S; Avci ME; Yilmaz C; Ertopcu K; Tinar S; Duman Y; Sayhan S
    Gynecol Oncol; 2008 Jan; 108(1):154-9. PubMed ID: 17945337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings.
    Inubashiri E; Hata K; Kanenishi K; Shiota A; Ohno M; Yamamoto Y; Nishiyama Y; Ohkawa M; Hata T
    J Obstet Gynaecol Res; 2009 Feb; 35(1):26-34. PubMed ID: 19215544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
    Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutch DG; Powell MA; Grigsby PW
    J Clin Oncol; 2010 Apr; 28(12):2108-13. PubMed ID: 20308664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
    Chang WC; Hung YC; Lin CC; Shen YY; Kao CH
    Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma.
    Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Mori A; Doi R; Ikai I; Uemoto S
    Surgery; 2008 Jun; 143(6):769-77. PubMed ID: 18549893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.
    Tsai CS; Lai CH; Chang TC; Yen TC; Ng KK; Hsueh S; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):477-84. PubMed ID: 19464824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area.
    Boughanim M; Leboulleux S; Rey A; Pham CT; Zafrani Y; Duvillard P; Lumbroso J; Haie-Meder C; Schlumberger M; Morice P
    J Clin Oncol; 2008 May; 26(15):2558-61. PubMed ID: 18487573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
    Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
    Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
    Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
    Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
    Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.